Table 2: Comparison between groups regarding clinical and angiographic outcome.
Variable | Control Group (n = 49) | Alteplase Group (n = 53) | P-Value | |
X ± SD | X ± SD | |||
Peak CK-MB (ug/L) | 146.3 ± 48.9 | 132.1 ± 54.4 | 0.17 | |
Peak Troponin I (ug/L) | 8.6 ± 3.2 | 7.1 ± 2.4 | 0.008 | |
ST resolution at 90 min | 34 (69.4%) | 46 (86.8%) | 0.033 | |
Final TIMI flow | 2 | 22 (44.9%) | 27 (55.1%) | 0.46 |
3 | 20 (37.7%) | 33 (62.3%) | ||
cTFC | 30.1 ± 3.3 | 19.3 ± 3.0 | < 0.001 | |
MBG | 1 | 15 (36.7%) | 11 (20.8%) | 0.03 |
2 | 26 (18.4%) | 21 (39.6%) | ||
3 | 8 (16.3%) | 21 (39.6%) | ||
TIMI Major bleeding | 0 | 0 | - | |
TIMI Minor/minimal bleeding | 4 (8%) | 6 (11.3%) | 0.24 | |
In-hospital reinfarction | 1 (2%) | 1 (1.9%) | 0.95 | |
Reinfarction within 6 months | 3 (6.1%) | 4 (7.5%) | 0.77 | |
Post-PCI angina | 3 (6.1%) | 2 (3.8%) | 0.58 | |
Recurrent angina within 6 months | 9 (18.4%) | 10 (18.9%) | 0.94 | |
Stent thrombosis | 0 | 0 | - | |
Target vessel revascularization | 3 (6.1%) | 2 (3.8%) | 0.58 | |
Cardiac death | 2 (4.1%) | 1 (1.9%) | 0.51 | |
Non-cardiac death | 1 (2%) | 1 (1.9%) | 0.95 |